As of November 6, 2026, one holder's latest Schedule 13D or 13G filing report owning 5% or more of Prokidney Corp. The largest reported stake is Control Empresarial de Capitales S.A. de C.V.'s, at 36%. 5 filings are on record since July 17, 2025 (Schedule 13D/A, April 30, 2026).
Sell to companies like Prokidney Corp? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Reporting person: Morgan Stanley · Sole voting: 0 · Shared voting: 9,349,605 · Sole dispositive: 0 · Shared dispositive: 9,646,889 · SCHEDULE 13G/A, 2026-08-12
- · Holder: Control Empresarial de Capitales S.A. de C.V. · Percent: 36% · SCHEDULE 13D/A
- · Holder: Morgan Stanley · Percent: 6% · SCHEDULE 13G
- · Holder: Morgan Stanley · Percent: 4.4% · SCHEDULE 13G/A
- · Holder: BlackRock, Inc. · Percent: 1.4% · SCHEDULE 13G/A
Prokidney Corp. has 5 Schedule 13D or 13G filings on record since 2025-07-17. 1 holder's latest filing reports 5% or more of class a common stock. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| Control Empresarial de Capitales S.A. de C.V. | 36% | 73,842,723 | SCHEDULE 13D/A, 2026-04-30 | 2026-04-28 |
| 4.7% | 9,653,756 | SCHEDULE 13G/A, 2026-08-12 | 2026-06-30 | |
| BlackRock, Inc. | 1.4% | 1,764,602 | SCHEDULE 13G/A, 2025-07-17 | 2025-06-30 |
Holding shares or following this stake? See who's behind Prokidney Corp. and the warning signs.
Free to see. No signup.
Keep reading
More on Prokidney Corp. and the records around it.
Prokidney Corp. elsewhere on the record
Companies that share a holder
- Morgan Stanley also filed stake reports on 182 other companies: MDA Space Ltd. (Nov 2026), RiverNorth/DoubleLine Strategic Opportunity Fund, Inc. (Oct 2026), Arbutus Biopharma Corp (Oct 2026)
- BlackRock, Inc. also filed stake reports on 1596 other companies: AvePoint, Inc. (Nov 2026), BIOMARIN PHARMACEUTICAL INC (Nov 2026), MSG RANGERS CORP (Nov 2026)
Watch Prokidney Corp.
Get an email when Prokidney Corp. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Prokidney Corp.?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Prokidney Corp.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Prokidney Corp. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
5 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Voting and dispositive power, as filed
| Reporting person | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Filing |
|---|---|---|---|---|---|
| Morgan Stanley | 0 | 9,349,605 | 0 | 9,646,889 | SCHEDULE 13G/A, 2026-08-12 |
| Morgan Stanley Investment Management Inc. | 0 | 9,338,841 | 0 | 9,642,992 | SCHEDULE 13G/A, 2026-08-12 |
The latest filing identifies Prokidney Corp. by CUSIP 74291D104 and gives its principal executive office as 2000 FRONTIS PLAZA BLVD., SUITE 250, WINSTON-SALEM, NC 27103 (SCHEDULE 13G/A, 2026-08-12).
Purpose of Transaction (Item 4)
Control Empresarial de Capitales S.A. de C.V.
Delaware Domestication On July 1, 2025, the Issuer effected a domestication from the Caymans Islands to the State of Delaware (the "Domestication"). Effective as of July 1, 2025, each (i) Class A ordinary share automatically converted into one share of Class A Common Stock of the Issuer and (ii) each Class B ordinary share automatically converted into one share of Class B common stock of the Issuer. Exchange Agreement Prior to April 28, 2026 (the "Transaction Date"), in addition to 10,724,078 shares of Class A Common Stock, the Reporting Persons beneficially owned 63,118,645 shares of Class B common stock of the Issuer held by Control Empresarial, each of which may, subject to the limitations set forth in the Amended and Restated Exchange Agreement and the Holdings LLCA (each as defined and as described in the Issuer's Current Report on Form 8-K filed with the SEC on July 3, 2025), be exchanged, together with the paired common unit in ProKidney Holdings, LLC (the "Paired Interests"), for a share of Class A Common Stock on a one-for-one basis. Control Empresarial held 63,118,645 Paired Interests prior to the Transaction Date. On the Transaction Date, Control Empresarial exchanged 63,118,645 Paired Interests for 63,118,645 shares of Class A Common Stock. As a result, as of the date of this filing, the Reporting Persons beneficially own 73,842,723 shares of Class A Common Stock.Item 4 of the SCHEDULE 13D/A filed 2026-04-30
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-07-17 | BlackRock, Inc. | 1.4% | SCHEDULE 13G/A |
| 2025-08-07 | Morgan Stanley | 4.4% | SCHEDULE 13G/A |
| 2026-02-12 | Morgan Stanley | 6% | SCHEDULE 13G |
| 2026-04-30 | Control Empresarial de Capitales S.A. de C.V. | 36% | SCHEDULE 13D/A |
| 2026-08-12 | Morgan Stanley | 4.7% | SCHEDULE 13G/A |
Questions about who owns Prokidney Corp.
Who owns Prokidney Corp.?
On this page, one holder's latest ownership filing reports 5% or more of Prokidney Corp.: Control Empresarial de Capitales S.A. de C.V. (36%, Schedule 13D/A, filed 2026-04-30).
When did Control Empresarial de Capitales S.A. de C.V. buy into Prokidney Corp.?
The filings give report dates, not purchase dates. The earliest filing from Control Empresarial de Capitales S.A. de C.V. on this page is the Schedule 13D/A, filed 2026-04-30, reporting 36%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 5 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Tools for this story
Each opens in a new tab, filled in for Prokidney Corp.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.